Antibody dealmaking driven by oncology
نویسندگان
چکیده
Recent major antibody deals involve immune checkpoint inhibitors, antibody–drug conjugates and natural killer cell engagers for cancer.
منابع مشابه
Capturing synergies in dealmaking
Acquirers can use company-specifi c synergies as a competitive advantage, particularly when they bid against private equity fi rms. Previously, private equity fi rms outbid strategic buyers by utilizing fi nancial leverage to achieve return goals. The current economic environment doesn’t enable that strategy; private equity fi rms can only embed synergies in their bid price when they merge the ...
متن کاملAntibody Therapeutics in Oncology
One of the newer classes of targeted cancer therapeutics is monoclonal antibodies. Monoclonal antibody therapeutics are a successful and rapidly expanding drug class due to their high specificity, activity, favourable pharmacokinetics, and standardized manufacturing processes. Antibodies are capable of recruiting the immune system to attack cancer cells through complement-dependent cytotoxicity...
متن کاملImplementing Genome-Driven Oncology
Early successes in identifying and targeting individual oncogenic drivers, together with the increasing feasibility of sequencing tumor genomes, have brought forth the promise of genome-driven oncology care. As we expand the breadth and depth of genomic analyses, the biological and clinical complexity of its implementation will be unparalleled. Challenges include target credentialing and valida...
متن کاملAntibody-driven psychosis
Psychotic episodes in lupus patients can be triggered by an antibody attack on brain cells, according to Matus et al. (page 3221). The psychosis that occurs in a small subset of lupus patients is associated with an antibody that recognizes a trio of ribosomal phosphoproteins. It was assumed that this antibody binds to the cell surface version of one of the phosphoproteins and somehow penetrates...
متن کاملAntibody Phage Display Libraries: Contributions to Oncology
Since the advent of phage display technology, dating back to 1985, antibody libraries displayed on filamentous phage surfaces have been used to identify specific binders for many different purposes, including the recognition of tumors. Phage display represents a high-throughput technique for screening billions of random fusion antibodies against virtually any target on the surface or inside can...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biopharma Dealmakers
سال: 2022
ISSN: ['2730-6275', '2730-6283']
DOI: https://doi.org/10.1038/d43747-022-00185-4